Higher serum levels of autotaxin and phosphatidylserine-specific phospholipase A1 in patients with lupus nephritis
Yasunori Iwata,Shinji Kitajima,Junya Yamahana,Shuji Shimomura,Shiori Yoneda-Nakagawa,Norihiko Sakai,Kengo Furuichi,Hisayuki Ogura,Koichi Sato,Tadashi Toyama,Yuta Yamamura,Taro Miyagawa,Akinori Hara,Miho Shimizu,Ryunosuke Ohkawa,Makoto Kurano,Yutaka Yatomi,Takashi Wada
DOI: https://doi.org/10.1111/1756-185X.14031
Abstract:Background: Recent studies revealed that lysophospholipids (LPLs) and related molecules, such as autotaxin (ATX) and phosphatidylserine-specific phospholipase A1 (PS-PLA1 ), are candidates for novel biomarkers in melanoma, glaucoma and diabetic nephropathy. However, it is not clear whether serum levels of ATX/ PS-PLA1 would be associated with pathological and clinical findings of lupus nephritis (LN). Methods: In this retrospective cohort study, serum samples were collected from 39 patients with LN and 37 patients with other glomerular diseases. The serum levels of ATX and PS-PLA1 were evaluated for an association with renal pathology and clinical phenotypes of LN. Results: The serum levels of ATX and PS-PLA1 were higher in the patients with LN as compared to those with other glomerular diseases. Among the classes of LN, the patients with class IV showed the trend of lower serum levels of ATX. Moreover, the patients with lower levels of ATX exhibited higher scores of activity index (AI) and chronicity index (CI). The level of ATX tended to be negatively correlated with AI and CI. These results might be explained by the effect of treatment, because the serum levels of ATX and PS-PLA1 were inversely correlated with the daily amount of oral prednisolone. Moreover, they did not reflect the level of proteinuria or kidney survival in LN patients. Conclusion: Although the serum levels of ATX and PS-PLA1 were affected by the treatment, these levels were higher in the patients with LN. The potential clinical benefits of these markers need to be clarified in further studies.